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Poster Session I S249relative orMatchedRelatedDonor (MRD). From1990 to 2007, a to-
tal of 15 pediatric or young adult patients with MDS received bone
marrow or cord blood transplant from an HLA matched sibling at
our institution. M:F ratio of the study group was 0.9; Two patients
belonged to ethnic minorities (13%); the median age at transplant
was 13.4 years (range 1.1-20.6) and median weight was 54.9 kg
(range 10.8-80.2). Three patients had therapy-related MDS (2
ALL, 1 NHL). MDS stage was RA/RC in 2 pts, RARS in 1 pt,
RAEB in 6 pts, RAEB-T in 2 pts, and AML in 4 pts. Monosomy 7
was present in 4 (27%) pts. Median time from diagnosis to transplant
was 3 months (range 1.3-25.8). Preparative regimen was non-TBI
based in 13 (87%) pts. TBI was used for 2 of the patients with
AML. Fourteen (93%) patients received melphalan. Cyclosporine
was used for GVHD prophylaxis with methotrexate in 12 pts and
Solu-medrol in 2 pts. The grafts (14 BM, 1UCB) contained amedian
of 2  10e8 (range 0.7-8.4) nucleated cells/kg infused. All patients
achieved neutrophil engraftment. Median time to neutrophil recov-
ery (ANC. 500) was 17 days (range 10-33), and that to platelet re-
covery (.50 K untransfused) was 43 days (range 21-150). Acute
GVHD, grade II-IV, was seen in 6 (40%) patients; none of the pa-
tients had grade III-IV acute GVHD. Chronic GVHD was seen in
4 (27%) patients, 2 limited (skin), and 2 extensive (skin, gut). The
only patient with RARS died from lactic acidosis secondary to
MELAS syndrome diagnosed post mortem. One patient, who had
undergone a prior transplant for ALL, acquired monosomy 7 clone
40months later. She underwent BMT from the same donor, relapsed
again after 22 months, underwent a third successful transplant from
the same donor with non-myeloablative conditioning and peripheral
blood stem cells. She is disease free 8 years from the last transplant.
Thus, 14 (93.3%) of the 15 patients are surviving long term and dis-
ease free with a median follow-up of 8.5 years (range 2.3-19). Bone
marrow or cord blood transplant from matched related donor with
non-TBI based, melphalan containing regimen is very effective in
curing MDS affecting children and young adults.244
HAEMATOPOIETIC STEM CELL TRANSPLANTATION FOR DNA-DSB RE-
PAIR DEFECTS USING A MODIFIED FANCONI ANAEMIA CONDITIONING
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Lymphocyte receptor generation requires proteins in the DNA-
double strand break (DNA-dsb) repair and non-homologous end-
joining pathway. Nibrin senses DNA-dsb, DNA ligase IV (LIG4)
and Cernunnos-XRCC4-like factor (C-XLF) ligate DNA-dsb to
form lymphocyte receptors, as well as general DNA-dsb repair. De-
ficiency of these enzymes confers radiosensitivity (RS) and primary
immunodeficiency (PID). Patients with PID due to deficiencies in
these genes are increasingly offered HSCT. Many conditioning reg-
imens (CR) damage DNA and RS patients die from CR toxicity; less
toxic CR are required to successfully treat these patients. We report
3 microcephalic RS patients treated using a modified Fanconi anae-
mia CR of C-1H 0.2 mg/KgD-9 –D-5, fludarabine 30 mg/m2D-9 –
D-5, cyclophosphamide 5 mg/kg D-5-D-2.
Patient 1 presented with prolonged RSV excretion. She had pan-
lymphopenia with marked CD8 lymphopenia, reduced PHA re-
sponse andpan-hypogammaglobulinaemiawith poor vaccine antigen
antibody responses. A homozygous 1089C.A mutation in NBS1
confirmed Nijmegen breakage syndrome. She underwent HLA-
identical sibling HSCT age 2 years. At 5 years post-HSCT she has
stable mixed donor chimerism in all cell lineages, with normal lym-
phocyte numbers and antibody responses to vaccine antigens.
Patient 2 presented with failure to thrive, persistent diarrhoea, re-
current respiratory infection and severe lymphopenia with hypogam-
maglobulinaemia. She had a homozygous c.833 G.A LIG4
mutation. She underwent a 9/10 (Amm) HLAmis-matched parental
HSCT aged 4.5 years. CSA and MMF were used as GvHD prophy-
laxis. Initial donor chimerism was 12%, but by 1 year post-HSCT
was 100% with full immunoreconstitution.
Patient 3 presentedwith developmental delay, severe lymphopenia
and hypogammaglobulinaemia, recurrent respiratory infection andcytomegaloviremia (CMV). He had a homozygous c.169C.Tmu-
tation in NHEJ1, confirming C-XLF deficient PID. He underwent
9/10 (Amm) HLA-mis-matched URD HSCT aged 3.5 years. CSA
andMMF were used as GvHD prophylaxis. Initial donor chimerism
was 25%, but by 2months postHSCTwas 100%.There was no con-
ditioning-related toxicity and immunoreconstitution at 4 months
was 100% donor. Subsequent complications included CMV reacti-
vation and skin and liver GvHD, from which he died at 358 days
post-HSCT. These, and a survey of other cases, demonstrate safety
and efficacy of this conditioning protocol. Further studies will be re-
quired to assess the long term outcome.245
PEDIATRIC AUTOLOGOUS PERIPHERAL BLOOD STEM CELL HARVEST
FACTORS AFFECTING TIME TO ENGRAFTMENT AND TRANSPLANT
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Intensive chemotherapy dependent on autologous stem cell trans-
plants (ASCT) is used in many protocols for solid tumors, including
brain tumors, and leukemias. ASCT allow the use of more intensive
chemotherapy and faster neutrophil and platelet recovery. Previous
studies have shown that the time to engraftment ranges from 9-28
days for neutrophils (ANC. 500/microliter). ASCT may also be
followed by engraftment toxicity, including fever, sepsis, shock,
and in rare instances, death. Between January 2001 and June 2009,
92 brain tumor, neuroblastoma, and primitive neuro-ectodermal tu-
mor patients (age 6 months to 27 years at transplant) underwent 186
peripheral blood ASCT at Children’s National Medical Center.
Multivariate analysis was used to determine variables affecting pa-
tient outcome measures (time to engraftment, transplant toxicity,
and time to pre-harvest absolute CD34+ peak). Transplant toxicity
was scored on an ordinal scale based on the severity of transplant-re-
lated complications. Independent variables analyzed included vari-
ables that were patient specific (age, weight, tumor type,
chemotherapy administered, and primary vs relapsed disease) and
those related to the harvest or transplant (WBC and CD34+ counts
prior to transplant and quantity of total nucleated cells and CD34+
cells infused during transplant). All cell counts were normalized to
patient weight.
Results:The time to engraftment post transplant was positively cor-
related with absolute CD34+ cells transfused (p5 0.01) and had
a less significant correlation with totalWBC and CD34% transfused
(p5 0.09). No significant correlation was found between platelet re-
covery and quantity of WBC or CD34+ cells transfused. Transplant
toxicity was significantly less with increasing with CD34+ and
CD34%, and was significantly greater in neuroblastoma patients.
The toxicity was significantly greater in younger patients. The
time to CD34+ recovery pre-harvest was significantly affected by pa-
tient diagnosis, chemotherapy regimen, and primary versus recur-
rent disease.
Conclusions: Infusion of larger numbers of CD34+ cells decreased
time to engraftment and transplant toxicity. In this pediatric popula-
tion, neuroblastoma patients and younger patients had more trans-
plant toxicity.246
A STUDY OF THE BARRIERS PREVENTING ACCESS OF U.S. PEDIATRIC
SICKLE CELL DISEASE PATIENTS TO TECHNOLOGIES THAT FACILITATE
COMPATIBLE SIBLING HEMATOPOIETIC CELL TRANSPLANTATION
Yang, J.C.1, Jae, G.1,2, Rahman, A.A.1, Shen, L.1, Lewkowitz, A.1,
Pearson, A.W.1, Sikorski, M.1, Del Toro, G.1 1Mount Sinai School of
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Children who receive hematopoietic cell transplantation (HCT)
for sickle cell disease (SCD) from an HLA-matched, SCD-free sib-
ling show disease-free survival of at least 85%, yet the majority of
children with SCD do not undergo HCT.
S250 Poster Session IStandard of care HCT requires the patient with SCD to be less
than 16 years of age and have an HLA-matched, SCD-free sibling.
However, only about 14% of children with SCD have such a sibling.
In-vitro fertilization combined with pre-implantation genetic diag-
nosis, known as in-vitro fertilization with therapeutic intent
(IVFTI), makes it possible for parents to select a compatible, unaf-
fected embryo to implant and carry to term.
European investigators have published the birth of matched,
SCD-free sibling donors via IVFTI, but in the United States it re-
mains unreported in the medical literature and appears underutil-
ized, begging the question of why this combination of therapeutic
procedures has not been more widely offered, performed, or re-
ported in the U.S. pediatric SCD community.
We interviewed 22 adult SCD patients and parents/caregivers of
pediatric SCD patients to better understand their attitudes toward
IVFTI and HCT, and the barriers that prevent use of these thera-
peutic procedures.
Most interviewees (20 of 22 subjects) believed that the benefits of
matched-sibling HCT to the child outweighed the risks.
Most interviewees (15) were unaware SCD could be cured by
HCT.
After learning about IVFTI, 14 interviewees were interested in
pursuing it. The vast majority of interviewees (19) believed that
IVFTI should be offered to all SCD families before their affected
child becomes HCT ineligible due to age.
Every interviewee (22) claimed that the cost of IVFTIwas a barrier
to access and that insurance coverage would increase IVFTI use.
Currently, IVFTI is not covered by a large number of insurance pro-
viders, including Medicaid.
Lack of information and high costs are twomajor barriers prevent-
ing children with SCD from benefiting from IVFTI.
Pediatric SCD patients’ lack of access to IVFTI and, therefore,
matched-sibling HCT demonstrates the extent to which healthcare
disparities plague the SCD community. As SCDprimarily affects Af-
rican-American and Latino children, most of whom subscribe to
Medicaid, the lack of awareness and underutilization of this available
combination of therapies is not only an issue of clinical importance,
but also one of social justice.247
HLA-MATCHED RELATED DONOR HEMATOPOIETIC STEM CELL TRANS-
PLANTATION IN 36 PEDIATRIC PATIENTS WITH SEVERE ACQUIRED
APLASTIC ANAEMIA
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Iravani, M., Mousavi, S.A., Bahar, B., Khodabandeh, A., Jalili, M. Teh-
ran University of Medical Sciences, Tehran, Islamic Republic of Iran
Objective: Severe acquired aplastic anemia (SAA) is a rare disease of
childhood. Matched related hematopoietic stem cell transplantation
(HSCT) is the treatment of choice for pediatric patients with SAA.
Immunosuppressive therapy is the alternative treatment in children
with SAA who do not have a donor. We retrospectively analyzed pe-
diatric patients who received allogeneic HSCT from HLA-matched
related donors at our institution.
Methods: Between March 1993 and October 2009, 36 patients (12
female, 24 male) below 15 years old with multitransfused SAA re-
ceived allogeneic HSCT fromHLA-matched related donors (33 sib-
lings and 3 other relatives). Median age was 11 years (range 1 to 15
years). The graft source was bone marrow in 22 patients, peripheral
blood stem cells in 13 patients and 1 patient received both bonemar-
row and peripheral blood. All patients were conditioned with a mye-
loablative regimen containing cyclophosphamide, and
antithymocyte globulin. For graft-versus-host disease (GVHD) pro-
phylaxis, we used cyclosporine and methotrexate at the standard
doses.
Results: With a median follow-up of 30 months (range, 1-106
months), overall survival was 94% and was not statistically signif-
icant different between the patients receiving bone marrow trans-
plants and those receiving peripheral blood transplants. The
median time to neutrophil engraftment (absolute neutrophil
count .0.510^9/L) was +13 and median time to platelet en-
graftment (platelet count .2010^9/L) was +19. Grade III–IV
acute GVHD occurred in 7(19.4%) patients. The cumulative in-cidence of chronic GVHD for those who survived more than 100
days was 8.3%. 2-year disease-free survival was 83.3% and 2-year
overall-free survival was 94%. At present 30 of 36 patients are
alive with normal hematologic parameters and full donor chime-
rism and doing well. The number of patients who not engrafted
was 4 (11.7%) and mortality rate was 2(5.5%).The causes of
death included infection in both of patients.
Conclusions:These results confirm previous studies that condition-
ing with amyeloablative regimen allows for sustained engraftment of
HLA-matched related donor grafts in most multitransfused SAA pe-
diatric patients and is associated with low incidences of GVHD, low
toxicity, and long-term survival.248
THE USE OF DAY 100 PLATELET COUNT TO IDENTIFY PEDIATRIC ALLO-
GENEIC HEMATOPOIETIC STEM CELL TRANSPLANT PATIENTS AT IN-
CREASED RISK OF MORTALITY
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Background: Scoring systems based on pre-hematopoietic stem
cell transplant (HSCT) evaluation and co-existing morbidities
have been validated and used to assign risk of adverse outcome,
particularly for adult patients. Currently, there is no standard
method of re-assessing risk for those who have survived the acute
transplant period. Despite advances in supportive care, patients
remain vulnerable to death from both relapse and transplant-re-
lated mortality (TRM) beyond the 100 day mark. Platelet counts
are easily obtainable and routinely checked at post-HSCT visits.
We analyzed the platelet count 100 days post transplant to deter-
mine if values \100,000 are associated with increased mortality
in pediatric allogeneic HSCT patients.
Methods: Retrospective data on 161 consecutive patients undergo-
ing allogeneic HCST at Children’s Hospital Boston/Dana Farber
from 1/1/05– 8/1/08 were reviewed; we report on 143 of the151 pa-
tients alive at D100. Patient age/gender, diagnosis, donor, condi-
tioning and post-transplant complications (GVHD, relapse and
death) were collected. Patients ranged in age from 0.14 to 21 (median
9)years. 58% received transplants from an unrelated donor. All had
fully ablative transplants, 74% TBI based.
Results: Patients with platelet counts\100,000 at D100 had
a significantly increased risk of mortality (OR 2.21,p \0.0001).
Mean platelet count of those alive versus dead at any time after
100 days was 181,000 vs 101,000 (p\0.001) and mean platelet
count of those alive vs dead at 1 year post-HSCT was
177,000 vs 100,000 (p5.0002). TRM was strikingly increased
for patients in the low platelet group (OR16, p\0.0001). Those
dying from transplant-related causes had a mean platelet value of
65,000 at D100 compared to a mean value of 175,000 for those
who did not (p\0.001) The mean platelet count at D 100 was
not significantly different in patients who relapsed vs those who
did not.
Conclusion: Our results indicate that D100 platelet count has sig-
nificant prognostic value for subsequent mortality even though the
causes of thrombocytopenia in this setting are diverse. The increased
risk is primarily due to an increase in TRM in those with counts
\100,000. After D100 patients often have fewer physician visits
and care shared with non-HSCT providers. D100 platelet count is
a simple, inexpensive and reliable marker that can be used to identify
patients at risk for an adverse transplant outcome thus prompting
further evaluation and/or closer followup.249
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